We demonstrated that persistent pharmacological activation of mDia using IMM02—a small molecule mDia agonist—indirectly disrupts the function of mDia in multiple patient-derived models of IDH-wild-type GBM. The gene discussed is IDH1; the disease is glioblastoma.